Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors

Brain

Volumn 123, Issue 4, 2000, Pages 733-745

  Fénelon, Gilles ^a   Mahieux, Florence ^a   Huon, Renaud ^a,b   Ziégler, Marc ^b  

^a HÔPITAL TENON   (France)

^b Léopold Bellan Hospital   (France)

Author keywords

Dementia; Hallucination; Parkinson's disease; Sleep wake disorder

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; COGNITION; DEMOGRAPHY; DEPRESSION; DISEASE DURATION; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PHENOMENOLOGY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SLEEP WAKING CYCLE; SOMNOLENCE; VISUAL HALLUCINATION;

EID: 0342424352     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.4.733     Document Type: Article

References (65)

1. Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. A community-based study. Arch Neurol 1999; 56: 595-601.
2. Ala TA, Yang KH, Sung JH, Frey WH 2nd. Hallucinations of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997; 62: 16-21.
3. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996; 47: 462-6.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington (DC): American Psychiatric Association; 1994.
5. Ballard C, Holmes C, McKeith I, Neill D. O'Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 1999; 156: 1039-45.
6. Barclay CL, Hildebrand K, Gray P, Mendis T, Mohr E, Grimes JD. Risk factors for the development of psychosis in Parkinson's disease [abstract]. Mov Disord 1997; 12 Suppl 1: 108.
7. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. [Review]. Trends Neurosci 1990; 13: 296-302.
8. Büttner T, Kuhn W, Müller T, Patzold T, Heidbrink K, Przuntek H. Distorted color discrimination in 'de novo' parkinsonian patients. Neurology 1995; 45: 386-7.
9. Büttner T, Kuhn W, Müller T, Welter FL, Federlein J, Heidbrink K, et al. Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease. J Neural Transm 1996; 103: 1195-204.
10. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34: 710-4.
11. Cummings JL. Managing psychosis in patients with Parkinson's disease [editorial]. N Engl J Med 1999; 340: 801-3.
12. de Ajuriaguerra J. Etude psychopathologique des parkinsoniens. In: de Ajuriaguerra J, Gauthier G, editors. Monoamines, noyaux gris centraux et syndrome de Parkinson. Genève: Masson; 1971. p. 327-55.
13. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998; 21: 289-95.
14. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 1989; 27: 1329-49.
15. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. [Review]. Adv Neurol 1995; 65: 115-38.
16. Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease, Vol. 2. Florham Park: Macmillan Healthcare Information; 1987. p. 153-63.
17. Fénelon G, Marie S, Ferroir JP, Guillard A. Hallucinose musicale: 7 cas. Rev Neurol (Paris) 1993; 149: 462-7.
18. Fernandez W, Stern G, Lees AJ. Hallucinations and parkinsonian motor fluctuations. Behav Neurol 1992; 5: 83-6.
19. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. [Review]. Ann Neurol 1997; 41: 706-15.
20. Friedman JH. The management of the levodopa psychoses. [Review]. Clin Neuropharmacol 1991; 14: 283-95.
21. Fuhrer R, Rouillon F. La version française de l'échelle CES-D (Center for Epidemiologie Studies - Depression scale). Description et traduction de l'échelle d'auto-évaluation. Psychiatrie Biol 1989; 4: 163-6.
22. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-9.
23. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669-71.
24. Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, et al. Intravenous levodopa infusions in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998a; 50: 515-7.
25. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998b; 51: 811-4.
26. Graham JM, Grünewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 434-40.
27. Grimby A. Bereavement among elderly people: grief reactions, post-bereavement hallucinations and quality of life. Acta Psychiatr Scand 1993; 87: 72-80.
28. Holroyd S, Sheldon-Keller A. A study of visual hallucinations in Alzheimer's disease. J Am Geriatr Soc 1995; 3: 198-205.
29. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
30. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 533-5.
31. Koller WC, Weiner WJ, Perlik S, Nausieda PA, Goetz CG, Klawans HL. Complications of chronic levodopa therapy: long-term efficacy of drug holiday. Neurology 1981; 31: 473-6.
32. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998; 121: 451-7.
33. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
34. Lhermitte J. Syndrome de la calotte du pédoncule cérébral. Les troubles psycho-sensoriels dans les lésions du mésencéphale. Rev Neurol (Paris) 1922; 38: 1359-65.
35. Mahieux F, Michelet D, Manifacier MJ, Boller F, Fermanian J, Guillard A. Mini-mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease. Behav Neurol 1995; 8: 15-22.
36. Mahieux F, Fénelon G. Prévalence des troubles neuropsychologiques au cours de la maladie de Parkinson. In: Gely-Nargeot MC, Ritchie K, Touchon J, editors. Actualités 1998 sur la maladie d'Alzheimer et les syndromes apparentés. Marseilles: Solal; 1998. p. 457-66.
37. Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 178-83.
38. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. [Review]. Brain 1998; 121: 1819-40.
39. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy body (DLB): report of the consortium on DLB international workshop. [Review]. Neurology 1996; 47: 1113-24.
40. McShane R, Gedling K, Reading M, McDonald B, Esiri MM, Hope T. Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1995; 59: 185-8.
41. Meco G, Bonifati V, Cusimano G, Fabrizio E, Vanacore N. Hallucinations in Parkinson disease: neuropsychological study. Ital J Neurol Sci 1990; 11: 373-9.
42. Mendis T, Barclay CL, Mohr E. Drug-induced psychosis in Parkinson's disease. A review of management. CNS Drugs 1996; 5: 166-74.
43. Mohr E, Mendis T, Grimes JD. Late cognitive changes in Parkinson's disease with an emphasis on dementia. [Review]. Adv Neurol 1995; 65: 97-113.
44. Moskovitz C, Moses H 3d, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669-75.
45. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc 1996; 44: 296-9.
46. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982; 5: 183-94.
47. Pappert EJ, Goetz CG, Raman R, Pass M, Leurgans S. Stability of hallucinations and illusions in Parkinson's disease: 18-month prospective study [abstract]. Mov Disord 1998; 13 Suppl 2: 90.
48. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 1999; 14: 117-21.
49. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. [Review]. Brain Cogn 1995; 28: 240-58.
50. Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhermitte F, Agid Y. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 1989; 52: 201-6.
51. Rees WD. The hallucinations of widowhood. Br Med J 1971; 4: 37-41.
52. Ribstein M. Hypnagogic hallucinations. In: Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy. New York: Spectrum; 1976. p. 145-60.
53. Rondot P, de Recondo J, Coignet A, Ziegler M. Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv Neurol 1984; 40: 259-69.
54. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. [Review]. Neurology 1993; 43 (12 Suppl 6): S47-52.
55. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996; 53: 1265-8.
56. Shergill SS, Walker Z, Le Katona C. A preliminary investigation of laterality in Parkinson's disease and susceptibility to psychosis [letter]. J Neurol Neurosurg Psychiatry 1998; 65: 610-11.
57. Shimomura T, Mori E, Yamashita H, Imamura T, Hirono N, Hashimoto M, et al. Cognitive loss in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 1998; 55: 1547-52.
58. Souques MA. Rapport sur les syndromes parkinsoniens. Rev Neurol (Paris) 1921; 37: 534-73.
59. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson disease. Arch Neurol 1997; 54: 625-30.
60. Tanner CM, Vogel C, Goetz CG, Klawans HL. Hallucinations in Parkinson's disease: a population study [abstract]. Ann Neurol 1983; 14: 136.
61. Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996; 347: 794-7.
62. Tulving E, Schacter DL. Priming and human memory systems. Science 1990; 247: 301-6.
63. Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J 1984; 289: 1101-3.
64. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997; 38: 797-802.
65. Vidailhet M, Bonnet AM, Belal S, Dubois B, Marle C, Agid Y. Ropinirole without levodopa in Parkinson's disease [letter]. Lancet 1990; 336: 316-7.